Nutrition band TruNativ raises $30M in Series B funding round led by OrbiMed

TruNativ, the Mumbai-based nutrition brand, has raised $30 million in a Series B round of funding led by OrbiMed, a healthcare focused investment firm.

The funding round comprised both primary investment and secondary transaction involving the early investors.

TruNativ will use the funds to expand its distribution network across D2C, quick commerce, modern trade, pharmacy, and other retail channels. The funding will also be used for the expansion of its B2B2C ingredient business.

Founded in 2019 by mother-son duo Pranav Malhotra and Mamta Malhotra, TruNativ is positioned as a clean-label nutrition platform spanning sugar alternatives, protein, gut health, and wellness. The brand claims that it currently holds a majority share of the sugar replacement category on quick-commerce platforms and ranks number one in the dietary fibre and sweeteners categories on Amazon India.

TruNativ co-founder & CEO Pranav Malhotra said, “India’s nutrition transformation is not a trend, it is a reckoning. For decades, Indian consumers have been underserved: overexposed to sugar, protein deficiency, and dependent on products that promise health but deliver compromise. We built TruNativ to fix that for every household, not just the health-conscious few.”

TruNativ has presence across five nutrition categories: sugar substitution (Everyday Sweet), protein (Everyday Protein, Pro Blend Whey), gut health (Everyday Fiber), beauty wellness (Advanced Collagen), and performance nutrition.

Sunny Sharma, Senior Managing Director, OrbiMed Asia said, “We share Pranav’s passion for improving nutrition nationwide and enhancing health outcomes through healthier daily dietary habits. OrbiMed is excited to partner with TruNativ as it builds a leading consumer health business.”

OrbiMed manages about $20 billion in assets across public equities, private equity, venture capital, and royalty strategies. It invests globally in companies developing transformative solutions across biotechnology, pharmaceuticals, medical devices, and healthcare services.